Biomedicine & Biotech

Join ACSH directors of bio-sciences and chemistry, Cameron English and Dr. Josh Bloom, as they break down these stories:
Pre-exposure prophylaxis (PrEP) is one of several historic breakthroughs in the four-decade battle against HIV/AIDS.
Just under two years ago, Canadian biotech firm Medicago began developing a plant-based COVID-19 vaccine.
Are COVID vaccines responsible for creating the multiple variants that keep hitting the world? I get this question all the time in the comments section following ACSH articles about vaccines.
The rapid development of mRNA-based COVID vaccines has sparked fresh interest in earlier efforts to produce new and hopefully more effective flu shots with the same technology.
Vaccine skepticism comes in many different varieties.
Since January, billions of COVID-19 vaccines have been administered around the world.
As if the Delta variant hasn't been a big enough pain in the a##, pretty much the last thing we need is an "improved" version.
There are now two direct-acting antiviral drugs that have been shown to decrease the severity of COVID, Gilead's remdesivir and Merck's molnupiravir.
Recent discussions on the economics of innovation in rapid diagnostic testing for bacterial infections in the hospital setting have inspired me to once again take pen (keyboard) in hand.
ACSH relies on donors like you. If you enjoy our work, please contribute.

Make your tax-deductible gift today!



Popular articles